Περίληψη:
Psoriasis is a chronic, immune-mediated disorder that usually requires
long-term treatment for control. Approximately 25% of patients have
moderate to severe disease and require phototherapy, systemic therapy or
both. Despite the availability of numerous therapeutic options, the
long-term management of psoriasis can be complicated by
treatment-related limitations. With advances in molecular research and
technology, several biological therapies are in various stages of
development and approval for psoriasis. Biological therapies are
designed to modulate key steps in the pathogenesis of psoriasis.
Collectively, biologicals have been evaluated in thousands of patients
with psoriasis and have demonstrated significant benefit with favourable
safety and tolerability profiles. The limitations of current psoriasis
therapies, the value of biological therapies for psoriasis, and guidance
regarding the incorporation of biological therapies into clinical
practice are discussed.
Συγγραφείς:
Sterry, W
Barker, J
Boehncke, WH
Bos, JD
Chimenti, S and
Christophers, E
de la Brassinne, M
Ferrandiz, C
Griffiths, C
and Katsambas, A
Kragballe, K
Lynde, C
Menter, A and
Ortonne, JP
Papp, K
Prinz, J
Rzany, B
Ronnevig, J and
Saurat, JH
Stahle, M
Stengel, FM
van de Kerkhof, P and
Voorhees, J
